<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073852</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <nct_id>NCT01073852</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Efficacy in Chronic Urticaria</brief_title>
  <official_title>Hydroxychloroquine Efficacy in Chronic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for those people with difficult to treat hives. We are investigating whether or&#xD;
      not a different medication, hydroxychloroquine, works to treat a certain type of hives.&#xD;
      Hydrochloroquine is currently approved by the Food and Drug Administration (FDA), for&#xD;
      treating arthritis, therefore it is considered investigational in this study.&#xD;
&#xD;
      Hypothesis: Hydroxychloroquine will prove to have an efficacious response in terms of&#xD;
      Urticarial Symptoms, on patients with chronic urticaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our research question is: Is hydroxychloroquine an efficacious medicine to use in patients&#xD;
      with chronic urticaria? Answering this question should help allergists treat chronic&#xD;
      urticaria with a more evidence based approach. To date there has one been one prospective&#xD;
      trial evaluating hydroxychloroquine in hives, and although it showed a trend towards efficacy&#xD;
      (0.05&lt;p&lt;0.10), it was not statistically significant. There have been case series, and&#xD;
      anecdotal reports which seem to demonstrate efficacy of chloroquine in chronic urticaria.&#xD;
      Because of these reports hydroxychloroquine is often the first medication used in patients&#xD;
      with chronic hives that are refractory to standard therapy of antihistamines. We believe an&#xD;
      evidence based answer to this question will be an important step towards improved treatment&#xD;
      of this disease.&#xD;
&#xD;
      We plan to ascertain the efficacy of hydroxychloroquine by completing a randomized double&#xD;
      blinded placebo controlled study of treatment in patients with chronic urticaria. We will be&#xD;
      measuring an Urticarial Score to evaluate hive symptoms. We will be measuring them at&#xD;
      baseline, and at the end of the study to note change in drug vs placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    withdrawn, not funded&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urticarial Symptom Score</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Basophil Activation</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Rescue Medication Usage</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Dermatology Life Quality Index</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be taking placebo medication throughout study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be taking hydroxychloroquine throughout study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill, 1 pill orally twice daily for 9 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Patients will be taking hydroxychloroquine 200mg orally twice/daily.</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion:&#xD;
&#xD;
               1. Age &gt;18, Age&lt;65&#xD;
&#xD;
               2. Chronic Urticaria refractory to treatment with standard anti-histamines&#xD;
&#xD;
               3. Minimum Urticaria Score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion:&#xD;
&#xD;
               1. Pregnancy&#xD;
&#xD;
               2. Vasculitis&#xD;
&#xD;
               3. Trigger Induced Urticaria&#xD;
&#xD;
               4. Food intolerance&#xD;
&#xD;
               5. Malignancy&#xD;
&#xD;
               6. Kidney or liver dysfunction&#xD;
&#xD;
               7. Systemic diseases&#xD;
&#xD;
               8. Hypersensitivity to hydroxychloroquine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pogie Pongonis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Fahrenholz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J. 2004 Apr;34(4):182-6.</citation>
    <PMID>15086698</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>John Michael Fahrenholz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic Urticaria</keyword>
  <keyword>Hives</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

